Myeloproliferative Neoplasms section

Myeloproliferative Neoplasms News & Features

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.

Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera

Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera

In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.

Effect of Myeloproliferative Neoplasm Diagnosis on Work, Employment Status

Effect of Myeloproliferative Neoplasm Diagnosis on Work, Employment Status

Using a cross-sectional online survey, researchers sought to determine how a MPN diagnosis affects work productivity and employment for patients with polycythemia vera, essential thrombocytopenia, or myelofibrosis.

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.

Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera

Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera

Researchers assessed outcomes for 587 patients with PV to determine the risk factors most likely to predict arterial or venous thrombosis in this patient population.

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

What is the concern behind PARP inhibitors and leukemia?

Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia

Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia

A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs